Business
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement observed at one month and three months12-letter BCVA gain and 23% CST reduction observed in the treated eye at three monthsFull cohort data expected in mid-year 2026 RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics”
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8o4zybgloi24hra3hobbTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0","width":300,"height":129}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months ","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Early signals of functional and structural improvement observed at one month and three months","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"12-letter BCVA gain and 23% CST reduction observed in the treated eye at three months","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Full cohort data expected in mid-year 2026","length":42,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":384,"olType":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today new clinical data from its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy, presented at the 49th Annual Meeting of the Macula Society, in San Diego, California.","length":475,"tagName":"p"},{"type":"text","content":"The presentation, titled “Preliminary Results from an Adult Participant in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations,” reported 3-month results from the first (sentinel) adult participant treated in the study, highlighting positive safety, tolerability, and biological activity following subretinal administration of OPGx-BEST1.","length":399,"tagName":"p"},{"type":"text","content":"The sentinel participant is a 63-year-old female with Autosomal-Recessive Bestrophinopathy (ARB) disease with seve...